By reducing cytokine release syndrome and neurotoxicity, prophylactic tocilizumab could facilitate safe outpatient ...

(MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy1,2 BEERSE, BELGIUM, Dec. 08, 2024 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a ...

Anita D'Souza, MD, discusses some of the potentially practice-changing data that were presented at the 2024 ASH Annual ...

Teclistamab maintenance, given alone or in combination with lenalidomide, appeared to be safe and demonstrated “unprecedented efficacy” in patients with multiple myeloma in the phase 3 MajesTEC-4 ...

Patients with newly diagnosed multiple myeloma experienced robust clinical activity when treated with Tecvayli (teclistamab) ...

Janssen-Cilag International NV, a Johnson & Johnson company, today announced new frontline data featuring TECVAYLI®▼ (teclistamab) from two investigational studies in patients with newly diagnosed ...

IVIG prophylaxis led to improvements in infection-free survival as well as progression free and overall survival in patients ...

Johnson & Johnson (JNJ) announced new frontline data featuring TECVAYLI (teclistamab-cqyv) from two investigational studies in ...

Simcha Therapeutics (“Simcha”), a clinical-stage immunobiology company pioneering first-in-class cytokine treatments in cancer, today announced the op ...

A woman with TEMPI syndrome who had a second relapse after many years of disease control with myeloma-type therapy had a rapid response to teclistamab, a bispecific antibody targeting plasma cells.

Teclistamab is recommended as an option for treating relapsed and refractory multiple myeloma in adults, only after 3 or more lines of treatment (including an immunomodulatory drug, a proteasome ...

Johnson & Johnson (NYSE:JNJ) today announced new frontline data featuring TECVAYLI® (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma (NDMM) in ...